Posted by Michael Wonder on 25 Aug 2018
ICER report finds evidence inadequate to distinguish the clinical benefits of different anti-androgen therapies for men with non-metastatic castration-resistant prostate cancer
24 August 2018 - Added costs of treating earlier stage disease with all therapies are aligned with their added clinical benefits for patients.
The ICER today released an evidence report assessing the comparative clinical effectiveness and value of anti-androgen therapies for the treatment of non-metastatic castration-resistant prostate cancer. The report focuses on three anti-androgen therapies: abiraterone acetate (Zytiga; Janssen), enzalutamide (Xtandi; Astellas) and apalutamide (Erleada; Janssen).
This evidence report will be the subject of an upcoming public meeting of the Midwest Comparative Effectiveness Public Advisory Council in Chicago on 13 September 2018.
